Gentronix Signs First Japanese Contracted Screening Collaboration with Kowa
News Oct 04, 2012
Under the agreement, Gentronix will conduct genotoxicity screening of compounds for Kowa for use in selected undisclosed therapeutic products in its development pipeline. Currently over 100 pharmaceutical and fine chemical companies in 17 countries have used the Gentronix proprietary GreenScreen HC assay technology as part of their genotoxicity profiling strategy.
“Gentronix is delighted to be working with Kowa in the Japanese market. We believe that the Gentronix GreenScreen assay with its outstanding specificity, high sensitivity and low compound requirement, is an ideal assay, as an early screen, to assist medicinal chemists make high quality compound decisions, improve attrition rates and avoid the late stage failure of drug candidates.” (John Nicholson, Gentronix CEO)
New Partnership to Provide Bioanalytical and DMPK ServicesNews
Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE